导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.83% | 3015/4773 |
| 近一周 | -2.67% | 2799/5462 |
| 近一月 | -5.64% | 3299/5421 |
| 近一季 | -8.05% | 2657/5209 |
| 近半年 | -4.16% | 2443/4920 |
| 近一年 | 0.24% | 2610/4366 |
| 近两年 | 40.75% | 1859/2954 |
| 近三年 | 22.81% | 1374/2253 |
| 成立以来 | 1.98% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.38% 3170/4961 |
12.10% 2229/5312 |
- - |
- - |
| 2025 | 20.80% 2089/4813 |
-0.02% 2030/3635 |
0.85% 2550/4076 |
19.95% 2068/4524 |
-0.12% 2370/4813 |
| 2024 | 13.30% 1155/3463 |
2.71% 725/2808 |
-1.10% 931/3014 |
15.65% 1661/3129 |
-3.55% 2364/3463 |
| 2023 | -10.98% 1356/2656 |
4.23% 1009/2280 |
-4.71% 1261/2385 |
-3.52% 946/2515 |
-7.11% 2053/2655 |
| 2022 | -19.74% 889/2207 |
-12.09% 571/1919 |
6.25% 739/2016 |
-14.82% 1155/2113 |
0.88% 1436/2208 |
| 2021 | -3.56% 912/1822 |
-1.05% 423/1255 |
1.37% 1057/1330 |
-5.48% 812/1466 |
1.72% 825/1822 |
| 2020 | - - |
- - |
- - |
- - |
- - |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 海富通中证A100指数(LOF)C VS. 长安沪深300非周期A(740101) |